Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma
Shots:
- The companies collaborated to evaluate TPST-1120 + Tecentriq (atezolizumab) and Avastin (bevacizumab) in P-Ib/II study in ~60 patients with advanced HCC prior not treated with HCC
- Tempest will retain the global rights to develop & commercialize TPST-1120 while Roche will manage the study operations for a global study
- TPST-1120 is a first-in-class selective PPAR⍺ antagonist with a two-pronged mechanism designed to target both tumor cells directly and suppressive immune cells in the tumor microenvironment. In extensive non-clinical studies- TPST-1120 as a monothx. or in combination with other drugs resulted in reductions of tumor growth and stimulation of durable anti-tumor immunity
Ref: Globe Newswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com